Article

Visiogen forms European subsidiary, releases accommodating IOL

During the winter meeting of the European Society of Cataract and Refractive Surgeons, held in early February here, Visiogen Inc. announced the formation of its European subsidiary, Visiogen Europe.

Rome

-During the winter meeting of the European Society of Cataract and Refractive Surgeons, held in early February here, Visiogen Inc. announced the formation of its European subsidiary, Visiogen Europe. Visiogen also announced that it will begin the controlled commercial release of its proprietary accommodating IOL (Synchrony) in Europe.

Visiogen was founded in Irvine, CA, in 2001. More than 1,000 of the accommodating lenses have been implanted in clinical trials.

During this recent ESCRS meeting, results from clinical research on the Synchrony dual optic accommodating IOL were featured in seven presentations and two posters. These included the initial results from new randomized, controlled European trials that compared the lens with an aspheric lens (AcrySof ReSTOR Aspheric, Alcon Laboratories) and a multifocal lens (Tecnis, Advanced Medical Optics), in which the accommodating IOL compared favorably. Results from a study from the University of Heidelberg showed objective dynamic accommodation with the accommodating lens at 5 years post-implantation.

“We are pleased with the growing interest in the [accommodating] IOL in Europe and the positive European clinical results that were presented in Rome,” said Stuart Windsor, managing director of Visiogen Europe, in a prepared statement. “The establishment of a permanent Visiogen presence in Europe is evidence of our commitment to supporting our European customers and to commercializing this exciting technology in a safe and responsible manner.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.